The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Open accessAbstract
Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-maximum group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-maximum group). The 1.5 mg-maximum group was included for exploratory purposes, and the data from that group were analyzed descriptively. Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible. The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 minutes. Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clinical worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety. Results By week 12, the 6-minute walk distance had increased by a mean of 30 m in the 2.5 mg-maximum group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P Conclusions Riociguat si…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that most efficacious therapies for the treatment of PH involve targeting of NO signaling[48,49], it is clear that pulmonary vascular health is intimately tied to effective NO bioactivity.”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [49]
Citations
Cites
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688
Self-citationSildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationRiociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393
Self-citationMiyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147
Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,000
Farber, H. W., Chakinala, M. M., Cho, M., Frantz, R. P., Frick, A., LANCASTER, L. H., Milligan, S., Oudiz, R. J., Panjabi, S. S., Tsang, Y., et al. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12258 · Cited by 9
Portopulmonary hypertension: A focused review for the internist
Chhabria, M., Boppana, L. K. T., Manek, G., & Tonelli, A. R. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.23023 · Cited by 9
Modulating NO–GC Pathway in Pulmonary Arterial Hypertension
D'Agostino, A. G., Lanzafame, L., Buono, L., Crisci, G., D’Assante, R., Leone, I., Vito, L. D., Bossone, E., Cittadini, A., & Marra, A. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010036 · Cited by 9
Said, K. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.21 · Cited by 9
Pharmacological treatment of HIV-associated pulmonary hypertension
Chinello, P., & Petrosillo, N. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1151785 · Cited by 9
Hirashiki, A., Adachi, S., Nakano, Y., Kamimura, Y., Shimokata, S., Takeshita, K., Murohara, T., & Kondo, T. (2016) · Pulmonary Circulation · doi:10.1086/685715 · Cited by 9
Effects of Omeprazole and Aluminum Hydroxide/Magnesium Hydroxide on Riociguat Absorption
Becker, C., Frey, R., Unger, S., Artmeier-Brandt, U., Weimann, G., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/682228 · Cited by 9
Poch, D. S. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0229-x · Cited by 9
Emerging drugs and therapeutics for systemic sclerosis
Lee, J. J., & Pope, J. E. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257607 · Cited by 9
Medical Treatment of Pulmonary Arterial Hypertension
Sahay, S., Humbert, M. J. C., & Sitbon, O. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1607208 · Cited by 9
Self-citationWang, J., Yeh, C., Chou, S.-J., Lu, K., Chu, T.-H., Chen, W., Chien, J.-L., Yen, M., Chen, T.-H., & Shyu, J. (2017) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-017-0866-z · Cited by 9
Alogna, A., Schwarzl, M., Manninger, M., Hamdani, N., Zirngast, B., Kloth, B., Paul Steendijk, A., Verderber, J., Zweiker, D., Westermann, D., et al. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00510.2017 · Cited by 9
Berlier, C., Schwarz, E. I., Saxer, S., Lichtblau, M., & Ulrich, S. (2019) · Lung · doi:10.1007/s00408-019-00222-7 · Cited by 9
Long-term survival outcome for pre-capillary pulmonary hypertension at a Japanese single center
Sugiyama, Y., Tahara, N., Bekki, M., Tahara, A., Honda, A., Maeda-Ogata, S., Sun, J., Igata, S., & Fukumoto, Y. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0663 · Cited by 9
Pharmacologic therapy for pulmonary artery hypertension
Nair, A. P. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000796 · Cited by 9
Kato, M., Sugimoto, A., & Atsumi, T. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1825940 · Cited by 9
Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat
Martynyuk, T. V., Shmalts, A. A., Gorbachevsky, S. V., & Chazova, I. E. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.09.201014 · Cited by 9
Portopulmonary hypertension: Current developments and future perspectives
Xu, H., Cheng, B., Wang, R., Ding, M., & Gao, Y. (2022) · Liver Research · doi:10.1016/j.livres.2022.02.002 · Cited by 9
Role of NO-cGMP-PKG axis in pulmonary arterial hypertension
Watanabe, H. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22018 · Cited by 9
Hill, N. S., Badesch, D. B., Benza, R. L., D’Eletto, T. A., Farber, H. W., Gomberg‐Maitland, M., Hassoun, P. M., & Preston, I. R. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201501-020as · Cited by 9
Riociguat for the treatment of pulmonary hypertension
Meis, T., & Behr, J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.964207 · Cited by 10
Pharmacogenetics of Cystic Fibrosis Treatment
Carter, S. C., & McKone, E. F. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.25 · Cited by 9
sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension
Benza, R. L., Mathai, S. C., & Nathan, S. D. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.010 · Cited by 10
Lin, H., Wang, M., Yu, Y., Qin, Z., Zhong, X., Ma, J., Zhao, F., & Zhang, X. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.11.002 · Cited by 9
Demerouti, E., Karyofyllis, P., Manginas, A., Anthi, A., Karatasakis, G., Athanassopoulos, G. D., & Voudris, V. V. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00319-z · Cited by 9
Rühle, A., Elgert, C., Hahn, M. G., Sandner, P., & Behrends, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173203 · Cited by 9
The evolving role of interventional cardiology in the treatment of pulmonary hypertension
Gurevich, S. G., & Prins, K. W. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29146 · Cited by 9
Selexipag for pulmonary arterial hypertension in a wide range of adult congenital heart disease
van Dissel, A. C., Post, M. C., Sieswerda, G. T., Vliegen, H. W., van Dijk, A. P. J., Mulder, B. J. M., & Bouma, B. J. (2021) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2021.100144 · Cited by 9
Nebivolol has a beneficial effect in monocrotaline-induced pulmonary hypertension
Pankey, E. A., Edward, J. A., Swan, K. W., Bourgeois, C. R. T., Bartow, M. J., Yoo, D., Peak, T. C., Song, B. M., Chan, R. A., Murthy, S. N., et al. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0431 · Cited by 9
Chizinga, M., & Fares, W. H. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.03.007 · Cited by 9
Zheng, Y., Ma, H., Chen, L., Jiang, X., Zhou, L., Lin, S., & Chen, S. (2018) · Pulmonary Circulation · doi:10.1177/2045894018798183 · Cited by 9
Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire
Reis, A., Twiss, J., Vicente, M., Gonçalves, F., Carvalho, L., Meireles, J., Melo, A., McKenna, S. P., & Almeida, L. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0513-8 · Cited by 9
Novel Pharmacological Targets for Pulmonary Arterial Hypertension
Klinger, J. R. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200015 · Cited by 10
Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways
Nubbemeyer, K., Krabbe, J., Böll, S., Michely, A., Kalverkamp, S., Spillner, J. W., & Martin, C. (2025) · Biomedicines · doi:10.3390/biomedicines13040856 · Cited by 8
Sweatt, A. J., Reddy, R., Rahaghi, F. N., Al‐Naamani, N., & American Thoracic Society Pulmonary Circulation Assembly Early Career Working Group (2021) · Pulmonary Circulation · doi:10.1177/20458940211040713 · Cited by 8
Zhao, J., Wang, Q., Wang, Q., Zhang, Y., Zhang, N., Zhang, R., Hao, Y., Jia, J., Li, M., & Zeng, X. (2021) · Rheumatology and Immunology Research · doi:10.2478/rir-2021-0010 · Cited by 8
Wang, P., Deng, J., Zhang, Q., Feng, H., Zhang, Y., Yi-zhong, L., Han, L., Yang, P., & Deng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.817119 · Cited by 8
Huang, W., Hsieh, S., Wu, Y., Hsieh, T., Wu, Y., Li, K., Charng, M., Chen, W., Sung, S., Tsao, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202303_39(2).20230117a · Cited by 8
MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension
He, Y., Wang, Y., Ma, J.-S., Li, R., Wang, J., Lian, T., Zhou, Y., Yang, H.-P., Sun, K., & Jing, Z. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107216 · Cited by 8
Self-citationClinical Utility of Patient-Reported Outcome Instruments in the Management of Pulmonary Hypertension
Rose, S. W., Highland, K. B., & Kelkar, A. A. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.09.008 · Cited by 8
Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension
Santos, R. T., Onofre, M. E. D. S. F., Caldeira, D. D. A. F., Belló‐Klein, A., Rocco, P. R. M., Cruz, F. F., & Silva, P. L. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611266576231211045731 · Cited by 8
Han, S. A., Han, S., Lee, J. S., Kang, D., Lee, J. S., Kim, D.-H., Park, D.-W., Song, J., Ryu, J., & Moon, D. H. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00858-1 · Cited by 8
Corboz, M. R., Nguyen, T. L., Stautberg, A., Cipolla, D. C., Perkins, W. R., & Chapman, R. W. (2024) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2024.0016 · Cited by 8
Kaufman, J., Nabozny, G. H., Manh, C. T., Liebel, C., Zhou, X., Daley, L.-A., Wang, C.-T., Ebenezer, D. L., Delić, D., Wohnhaas, C. T., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf109 · Cited by 8
Influence of riociguat treatment on pulmonary arterial hypertension
Zhao, R., & Jiang, Y. (2018) · Herz · doi:10.1007/s00059-018-4697-z · Cited by 8
Perioperative Management of Pulmonary Endarterectomy—Perspective from the UK National Health Service
Ng, O., Giménez‐Milà, M., Jenkins, D. P., & Vuylsteke, A. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.11.033 · Cited by 8
Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior Trials
Thakker, R. A., Elbadawi, A., Albaeni, A., Perez, C., Hasan, S. M., Murrieta, J. I., Almustafa, A., Duarte, A. G., Berbarie, R. F., Chatila, K. F., et al. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100924 · Cited by 8
Urbanowicz, R. J., Holmes, J. H., Appleby, D. H., Narasimhan, V., Durborow, S., Al‐Naamani, N., Fernando, M., & Kawut, S. M. (2021) · Methods of Information in Medicine · doi:10.1055/s-0041-1739361 · Cited by 8
Pediatric Pulmonary Arterial Hypertension
Wu, D., Zhang, H., & Jing, Z. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0399-3 · Cited by 8
Self-citationPulmonary Hypertension Complicating Connective Tissue Disease
Belperio, J. A., Saggar, R., Fishbein, M. C., Saggar, R., & Lynch, J. P. (2013) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0033-1356547 · Cited by 8
van Heerebeek, L. (2014) · SOJ Pharmacy & Pharmaceutical Sciences · doi:10.15226/2374-6866/1/2/00112 · Cited by 8
Clinical trials in pulmonary sarcoidosis
Baughman, R. P., Lower, E. E., & Saketkoo, L. A. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000193 · Cited by 8
Mondritzki, T., Boehme, P., Schramm, L., Vogel, J. K., Mathar, I., Ellinghaus, P., Kolkhof, P., Bischoff, E., Hüser, J., Dinh, W., et al. (2017) · European Journal of Applied Physiology · doi:10.1007/s00421-017-3761-3 · Cited by 8
Rippe, C., Albinsson, S., Guron, G., Nilsson, H., & Swärd, K. (2018) · Acta Physiologica · doi:10.1111/apha.13094 · Cited by 8
CONTEMPORARY STRATEGY OF PULMONARY HYPERTENSION MANAGEMENT IN PEDIATRICS
Miklashevich, I. M., Shkolnikova, M. A., Gorbachevsky, S. V., Shmalts, A. A., Groznova, O. S., Sadykova, D. I., Yakovleva, L. V., Degtyarev, D. N., Александрович, Б. А., Ovsyannikov, D. Y., et al. (2018) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2018-2-101-124 · Cited by 8
Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis
Wang, L., Zhu, L., Wu, Y., Li, Q., & Liu, H. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-2656 · Cited by 8
Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?
Klinger, J. R. (2016) · European Respiratory Journal · doi:10.1183/13993003.01542-2016 · Cited by 8
Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions
Diab, N., & Hassoun, P. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.00522-2017 · Cited by 8
Hu, X., Ding, N., Songchen, W., Wang, R., Chen, J., Zhong, A., Nan, J., Zuo, Y., Huang, H., & Tian, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080350 · Cited by 7
Hersi, K., Ramani, G. V., Law, J. Y., Sadek, A. S., Vaidya, A., Gladwin, M. T., & Cassady, S. J. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12362 · Cited by 7
Legchenko, E., Chouvarine, P., Hysko, K., Qadri, F., Wesołowski, R., Specker, E., Glage, S., Meier, M., Schwarz, K., Heineke, J., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0365oc · Cited by 7
Varian, F., Burney, R., Pearson, C., Goh, Z. M., Newman, J. V., Rawlings, G. H., Zafar, H., Kiely, D. G., Thompson, A. A. R., Condliffe, R. A., et al. (2025) · European Respiratory Review · doi:10.1183/16000617.0006-2025 · Cited by 8
Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure
Gawryś, O., Kala, P., Šnorek, M., Melenovský, V., Corda, S., & Sandner, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117363 · Cited by 7
Future Therapies in PAH: Update on the New Landscape and Drugs in the Pipeline
Preston, I. R. (2014) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-13.2.76 · Cited by 7
Blok, I. M., van Riel, A. C. M. J., Mulder, B. J. M., & Bouma, B. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1101341 · Cited by 7
Advances in the discovery of drugs that treat pulmonary arterial hypertension
Zolty, R. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2192919 · Cited by 7
McChord, J., Pereyra, V. M., Froebel, S., Bekeredjian, R., Schwab, M. G., & Ong, P. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1156456 · Cited by 7
Diagnosis and Management of Pulmonary Hypertension: New Insights
Ntiloudi, D., Kasinos, N., Kalesi, A. E., Vagenakis, G. A., Theodosis-Georgilas, A., & Rammos, S. (2024) · Diagnostics · doi:10.3390/diagnostics14182052 · Cited by 7
Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies
Tsai, J. C.-S., Malik, S., & Tjen‐A‐Looi, S. C. (2024) · Life · doi:10.3390/life14101265 · Cited by 7
Functional Measures in Non-COPD Chronic Respiratory Diseases: A Systematic Review
Zamboti, C. L., Pimpão, H. A., Bertin, L. D., Krinski, G. G., Garcia, T., Filho, S. L. S. D. S., Cavalheri, V., Pitta, F. D. O., & Camillo, C. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226887 · Cited by 7
Villar, A. B., Pousada, G., Pombo, C. V., Fernández, M. N., Martínez, J. M. C., & Valverde, D. (2014) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.10.016 · Cited by 7
Hipertensión portopulmonar: Revisión actualizada
Rodríguez-Almendros, N. A., Toapanta-Yanchapaxi, L. N., Aguirre-Valádez, J., Espinola-Zavaleta, N. G., Muñoz, S., & García‐Juárez, I. (2016) · Archivos de cardiología de México · doi:10.1016/j.acmx.2016.11.002 · Cited by 7
Effects of inorganic nitrate in a rat model of monocrotaline‐induced pulmonary arterial hypertension
Malikova, E., Carlström, M., Kmecová, Z., Marušáková, M., Zsigmondova, B., Křenek, P., Klimas, J., & Henrohn, D. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13309 · Cited by 7
Banijamali, A. R., Carvalho, A., WAKEFIELD, J. D., Germano, P., Barden, T. C., Tobin, J. V., Zimmer, D. P., Masferrer, J. L., Profy, A. T., Currie, M. G., et al. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.579 · Cited by 7
Ghofrani, H., Grünig, E., Jansa, P., Langleben, D., Rosenkranz, S., Preston, I. R., Rahaghi, F., Sood, N., Busse, D., Meier, C., et al. (2020) · Pulmonary Circulation · doi:10.1177/2045894020942121 · Cited by 7
Self-citationGonzaga‐Costa, K., Roque, C. R., Vasconcelos‐Silva, A. A., Sousa‐Brito, H. L., Martins, C. S., Ceatano-Souza, M. M., Duarte, G. I. B. P., da Silva, J. K. R., Borges, R. S., dos Santos, A. A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119334 · Cited by 7
Evidence base for specific pulmonary vasodilators in adults with congenital heart disease
Shmalts, A. A., & Gorbachevsky, S. V. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.09.201022 · Cited by 7
Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside
Mazzola, M., Madonna, R., Badagliacca, R., & Caterina, R. D. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107022 · Cited by 7
The role of riociguat in combination therapies for pulmonary arterial hypertension
Rahaghi, F., Trivieri, M. G., & Sahay, S. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107196 · Cited by 7
Morales‐Cano, D., Izquierdo-García, J. L., Barreira, B., Esquivel‐Ruiz, S., Callejo, M., Pandolfi, R., Villa, P., Rodríguez, I., Cogolludo, A. L., Ruı́z-Cabello, J., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1021535 · Cited by 7
Banaszkiewicz, M., Kurzyna, P., Kubikowska, N., Mucha, M., Rudnik, A., Gąsecka, A., Pietrasik, A., Grabowski, M., Jaguszewski, M. J., Kasprzyk, P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165336 · Cited by 7
Zhang, L., Troccoli, C. I., Mateo-Victoriano, B., Lincheta, L. M., Jackson, E., Shu, P., Plastini, T. M., Tao, W., Kwon, D., Chen, X., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0133 · Cited by 7
Wheeler, W. M. (1923) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.25193 · Cited by 7
Actualización en hipertensión arterial pulmonar
Mejía-Chew, C., Batres, S. A., & Blanco, J. J. R. (2016) · Revista Clínica Española · doi:10.1016/j.rce.2016.04.002 · Cited by 7
Cheong, F.-Y., Gower, A. C., & Farber, H. W. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.05.015 · Cited by 7
Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies
Kanwar, M. K., Raina, A., Passineau, M. J., & Benza, R. L. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1606317 · Cited by 7
Krasowska, D., Rudnicka, L., Dańczak‐Pazdrowska, A., Chodorowska, G., Woźniacka, A. J., Lis‐Święty, A., Czuwara, J., Maj, J., Majewski, S. T., Sysa‐Jędrzejowska, A., et al. (2017) · Dermatology Review · doi:10.5114/dr.2017.71831 · Cited by 7
New and emerging treatments for vaso-occlusive pain in sickle cell disease
Dampier, C. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1649131 · Cited by 7
Petrovič, M., & Locatelli, I. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0037 · Cited by 7
Macitentan in the Treatment of Pulmonary Arterial Hypertension
Zebadúa-Torres, R., Hernández‐Pérez, A., Garcia, A. C. M., Zayas, N., Sandoval, J., López, J., & Pulido, T. (2020) · Future Cardiology · doi:10.2217/fca-2020-0012 · Cited by 7
Selexipag for the treatment of pulmonary arterial hypertension
Richter, M. J., Gall, H. J., Grimminger, J., Grimminger, F., & Ghofrani, H. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215429 · Cited by 7
Self-citationNelissen, E., van Hagen, B. T. J., Argyrousi, E. K., van Goethem, N. P., Heckman, P. R. A., Paes, D., Mulder-Jongen, D., Ramaekers, J. G., Blokland, A., Schmidt, H. H. H. W., et al. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136840 · Cited by 7
Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?
McGoon, M. D. (2014) · European Respiratory Journal · doi:10.1183/09031936.00039314 · Cited by 7
Torre, D. E., & Pirri, C. (2025) · Medical Sciences · doi:10.3390/medsci13040210 · Cited by 6
Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives
Humbert, M. J. C., Zeder, K., Kovács, G., & Weatherald, J. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079274 · Cited by 6
Self-citationTang, C. N., Lee, K.-L., & Ying, K.-Y. (2016) · Hong Kong bulletin on rheumatic diseases · doi:10.1515/hkbrd-2016-0004 · Cited by 6
REPLACE and the role of riociguat in pulmonary arterial hypertension therapy
Frantz, R. P. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30567-1 · Cited by 6
Recent developments in cGMP research: From mechanisms to medicines and back
Łukowski, R., & Feil, R. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15824 · Cited by 6
Olsson, K. M., Fuge, J., Park, D., Kamp, J. C., Brod, T., Harrigfeld, B., Schupp, J. C., & Hoeper, M. M. (2023) · European Respiratory Journal · doi:10.1183/13993003.01070-2023 · Cited by 6
Pulmonary Hypertension in Underrepresented Minorities: A Narrative Review
Contreras, J., Nussbaum, J. S., Cangialosi, P., Thapi, S., Radakrishnan, A., Hall, J., Ramesh, P., Trivieri, M. G., & Sandoval, A. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010285 · Cited by 6
Metadata
- Authors
- Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., Neuser, D., & Rubin, L. J.
- Affiliations
- Justus-Liebig-Universität Gießen (DE)
- University of Bologna (IT)
- University Hospital Heidelberg (DE)
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- St Vincent's Hospital Sydney (AU)
- Jewish General Hospital (CA)
- Bayer (Italy) (IT)
- Bayer (Germany) (DE)
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 330-340
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107011819
- Cited by
- 1,346
- References
- 26
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 75 · 2023: 90 · 2022: 98 · 2021: 112 · 2020: 93 · 2019: 85 · 2018: 92 · 2017: 115 · 2016: 145 · 2015: 152 · 2014: 128 · 2013: 32
- FWCI
- 124.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- riociguat, pulmonary arterial hypertension, soluble guanylate cyclase stimulator, 6-minute walk distance, pulmonary vascular resistance, NT-proBNP, WHO functional class, dyspnea, endothelin receptor antagonists, prostanoids, dose adjustment, syncope, exercise capacity, quality of life, drug safety, drug efficacy
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypertension, Pulmonary, Male, Middle Aged, Peptide Fragments, Prostaglandins, Pyrazoles, Pyrimidines, Quality of Life, Vascular Resistance, Walking, Exercise Tolerance, Natriuretic Peptide, Brain, Endothelin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
